Edoxaban tosylate monohydrate
- Catalog NO.：A890878
- CAS No. : 1229194-11-9
- Molecular Formula：C31H40ClN7O8S2
- Molecular Weight： 738.27
1. Please click the
to confirm the discount and stock quantity.2. Click“Bulk Inquiry”to ask for quotations of other quantity.
3. The price does not include shipping and bank charges.
Product Details
| CAS Number | 1229194-11-9 | Appearance | |
| Catalog Number | A890878 | MDL Number | MFCD28400751 |
| Molecular Formula | C31H40ClN7O8S2 | Molecular Weight | 738.27 |
| Boiling Point | Melting Point | ||
| Flash Point | Density | ||
| Synonyms | N1-(5-chloropyridin-2-yl)-N2-((1S,2R,4S)-4-(dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamido)cyclohexyl)oxalamide 4-methylbenzenesulfonate hydrate | ||
| Storage Condition | Store in a tightly closed container,in a cool and dry place | ||
Safety
| GHS Pictogram |
|
||
| Signal Word | Warning | UN Number | |
| Hazard Statements | H302-H315-H319-H335 | Class | |
| Precautionary Statements | P261-P305+P351+P338 | Packing Group | |
Description
|
Edoxaban (INN, codenamed DU-176b, trade name Lixiana) is a potent, selective factor Xa inhibitor, which has good oral bioavailability. Edoxaban is an anticoagulant drug which acts as a direct factor Xa inhibitor. It is being developed by Daiichi Sankyo. It was approved in July 2011 in Japan for prevention of venous thromboembolisms (VTE) following lower-limb orthopedic surgery. It was also approved by the FDA in January 2015 for the prevention of stroke and non–central-nervous-system systemic embolism. |
